Akebia Therapeutics Inc
F:AX9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akebia Therapeutics Inc
F:AX9
|
US |
|
Masivo Silver Corp
XTSX:MASS
|
CA |
|
S
|
Societe Generale SA
XMUN:SGE
|
FR |
|
T
|
Tonnellerie Francois Freres SA
F:5L1
|
FR |
|
Arctic Paper SA
F:A0P
|
PL |
|
F
|
Flutter Entertainment PLC
F:PPB
|
IE |
|
N
|
Newmont Corporation
F:NMM
|
US |
|
C
|
Caixabank SA
XMUN:48CA
|
ES |
Wall St Price Targets
AX9 Price Targets Summary
Akebia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AX9 is 7.663 EUR with a low forecast of 5.174 EUR and a high forecast of 10.757 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AX9's stock price target?
Price Target
7.663
EUR
According to Wall Street analysts, the average 1-year price target for AX9 is 7.663 EUR with a low forecast of 5.174 EUR and a high forecast of 10.757 EUR.
What is the Revenue forecast for Akebia Therapeutics Inc?
Projected CAGR
12%
The compound annual growth rate for Revenue over the next 8 years is 12%.
What is the Operating Income forecast for Akebia Therapeutics Inc?
Projected CAGR
39%
The compound annual growth rate for Operating Income over the next 8 years is 39%.
